Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorGuangzhou 8th People's Hospital
About this trial
This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and/or sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world
Eligibility criteria
Qualifiers
Confirmed HIV infection;
Progression to AIDS stage: CD4+ count <200 cells/ul and/or occurrence of AIDS opportunistic infections;
Age between 18 and 65 years;
The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;
Disqualifiers
Coexisting central nervous system lesions, severe liver disease, or cirrhosis;
Concurrent AIDS-related or unrelated tumors;
Women who are pregnant or breastfeeding;
Severe underlying diseases of the heart, lungs, liver, kidneys, etc.;
Trial design
Treatments tested in this trial
- Pathogen metagenomic next-generation sequencing
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov